Email this article Opposite Effects of Histone H1 and HMGN5 Protein on Distant Interactions in Chromatin
- Authors: Nizovtseva E.V.1, Polikanov Y.S.2,3, Kulaeva O.I.1, Clauvelin N.4, Postnikov Y.V.5, Olson W.K.4, Studitsky V.M.1,6
-
Affiliations:
- Cancer Epigenetics Program, Fox Chase Cancer Center
- Department of Biological Sciences, University of Illinois at Chicago
- Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago
- Department of Chemistry and Chemical Biology, BioMaPS Institute for Quantitative Biology, Rutgers, the State University of New Jersey
- Protein Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute
- Faculty of Biology, Moscow State University
- Issue: Vol 53, No 6 (2019)
- Pages: 912-921
- Section: Molecular Cell Biology
- URL: https://journals.rcsi.science/0026-8933/article/view/164133
- DOI: https://doi.org/10.1134/S002689331906013X
- ID: 164133
Cite item
Open Access
Access granted
Subscription Access
Abstract
Transcriptional enhancers in the cell nuclei typically interact with the target promoters in cis over long stretches of chromatin, but the mechanism of this communication remains unknown. Previously we have developed a defined in vitro system for quantitative analysis of the rate of distant enhancer-promoter communication (EPC) and have shown that the chromatin fibers maintain efficient distant EPC in cis. Here we investigate the roles of linker histone H1 and HMGN5 protein in EPC. A considerable negative effect of histone H1 on EPC depending on its C- and N-tails was shown. Protein HMGN5 that affects chromatin compaction and is associated with active chromatin counteracts EPC inhibition by H1. The data suggest that the efficiency of the interaction between the enhancer and the promoter depends on the structure and dynamics of the chromatin fiber localized between them and can be regulated by proteins associated with chromatin.
About the authors
E. V. Nizovtseva
Cancer Epigenetics Program, Fox Chase Cancer Center
Email: vasily.studitsky@fccc.edu
United States, Philadelphia, PA, 19422
Y. S. Polikanov
Department of Biological Sciences, University of Illinois at Chicago; Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago
Email: vasily.studitsky@fccc.edu
United States, Chicago, IL 60607; Chicago, IL 60607
O. I. Kulaeva
Cancer Epigenetics Program, Fox Chase Cancer Center
Email: vasily.studitsky@fccc.edu
United States, Philadelphia, PA, 19422
N. Clauvelin
Department of Chemistry and Chemical Biology, BioMaPS Institute for Quantitative Biology,Rutgers, the State University of New Jersey
Email: vasily.studitsky@fccc.edu
United States, Piscataway, NJ 08854
Y. V. Postnikov
Protein Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute
Email: vasily.studitsky@fccc.edu
United States, Bethesda, NIH, MD 20892
W. K. Olson
Department of Chemistry and Chemical Biology, BioMaPS Institute for Quantitative Biology,Rutgers, the State University of New Jersey
Email: vasily.studitsky@fccc.edu
United States, Piscataway, NJ 08854
V. M. Studitsky
Cancer Epigenetics Program, Fox Chase Cancer Center; Faculty of Biology, Moscow State University
Author for correspondence.
Email: vasily.studitsky@fccc.edu
United States, Philadelphia, PA, 19422; Moscow, 119991
